newsfilter
← Latest News
PR Newswire·

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest...